Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has received approval from the National Medical Products Administration of China for its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution," marking a significant milestone in its product development [1][2]. - The company has successfully launched two key Class III medical devices, enhancing its competitive edge in the recombinant collagen sector [3]. - The dual product strategy addresses both wrinkle reduction and skin quality improvement, catering to diverse consumer needs in the aesthetic medicine market [2][3]. Financial Projections - Revenue is projected to grow from 3,524 million in 2023 to 7,204 million in 2027, with a peak growth rate of 57.2% in 2024 [4]. - Net profit is expected to increase from 1,452 million in 2023 to 2,630 million in 2027, with a notable growth rate of 44.9% in 2023 [4]. - Earnings per share (EPS) are forecasted to rise from 1.49 in 2023 to 2.46 in 2027, reflecting a strong upward trend in profitability [4]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 21.1 in 2023 to 12.8 in 2027, indicating an improving valuation as earnings grow [4]. - The price-to-book (P/B) ratio is expected to decline from 7.2 in 2023 to 2.7 in 2027, suggesting a more favorable valuation relative to book value over time [4].

Core Viewpoint - The cosmetic industry faces its first IPO termination case in 2026, as Chuang'er Bio announces the cessation of its listing guidance due to unresolved shareholder equity freeze issues, marking its second failed IPO attempt [1][3][11]. Group 1: IPO Termination Reasons - The termination of the IPO guidance is attributed to the long-term unresolved issue of shareholder equity freeze, particularly involving the second-largest shareholder Ding Yumei, whose shares are frozen due to legal actions related to Evergrande's debt crisis [3][5][8]. - The company had previously attempted to go public, facing setbacks including two failed applications to the Sci-Tech Innovation Board and a subsequent shift to the Beijing Stock Exchange, which also did not yield results [10][11]. Group 2: Financial Performance and Challenges - Chuang'er Bio has struggled with fluctuating financial performance, with revenue consistently hovering between 240 million and 400 million RMB over the past six years, indicating a clear growth ceiling [12][14]. - The company's revenue for 2025 was reported at 214 million RMB for the first half, reflecting a year-on-year increase of 16.98%, but net profit plummeted by 55.99% to 13.21 million RMB, highlighting a trend of "increased revenue without increased profit" [13][14]. Group 3: Industry Context and Competitive Landscape - The collagen market is projected to surpass hyaluronic acid, becoming the leading ingredient in skincare by 2025, with a forecasted market size of 108.3 billion RMB by 2027, growing at a compound annual growth rate of 42.4% [16]. - Competitors like Juzhi Bio and Jinbo Bio have significantly outpaced Chuang'er Bio in both revenue and profitability, with Juzhi Bio's revenue soaring from 2.36 billion RMB in 2022 to 5.54 billion RMB in 2024, while Chuang'er Bio's growth remains stagnant [17][20]. Group 4: Regulatory and Technological Challenges - Regulatory tightening and the decline of the "medical device" business model have adversely affected Chuang'er Bio, which previously relied on its medical dressing products for competitive advantage [18]. - The shift in technology from animal-derived collagen to recombinant collagen has created a gap, with competitors advancing in this area while Chuang'er Bio remains focused on traditional collagen products [19][20]. Group 5: Future Outlook - The termination of the IPO is seen as a culmination of long-standing issues in industry competition, technological positioning, and capital utilization, suggesting that Chuang'er Bio must find a sustainable growth engine and differentiate itself in a competitive landscape to consider future IPO attempts [21].

Core Insights - The article highlights the evolving consumer demand for skincare products, emphasizing the importance of long-term skin safety and the role of advanced technology in meeting these needs. The company, Giant Bio, is positioned as a leader in the recombinant collagen field, redefining the value of biotech firms in the eyes of consumers [1] Group 1: Clinical Evidence and Trust - Giant Bio establishes a foundation of trust through clinical data supporting its recombinant collagen technology. At the CDA2025 conference, research showed significant improvement in facial erythema for patients using products containing recombinant collagen, providing clear, visual results that shift consumer choice from marketing claims to scientifically backed evidence [3] - The transition from potential effectiveness to confirmed effectiveness represents the core value that Giant Bio creates for consumers [3] Group 2: Professional Application and Safety - In the specialized post-aesthetic care scenario, consumer demands are more stringent. Giant Bio extended its product efficacy validation to professional fields such as laser skin repair, exploring solutions through extensive research and clinical evidence. This indicates that choosing Giant Bio means opting for a clinically validated safety solution [4] - The application research on infant vascular tumors further underscores the brand's commitment to safety [4] Group 3: Emotional Connection and Brand Differentiation - Beyond addressing skin issues, Giant Bio integrates emotional needs into its product offerings through initiatives like "My 'Recombinant' Relationship," showcasing deep insights into consumer psychology [5] - The brand's "Health Living Toolbox" concept merges high-tech products with everyday care, breaking down the barriers between professional and daily use. This strategy enhances product convenience and allows technological innovation to gently enter consumers' lives [7] - The focus on emotional health transforms products from mere functional attributes into a part of users' self-identity, establishing a unique differentiation advantage in a competitive market [7] Group 4: Transparency and Consumer Assurance - In an era of increasing information transparency, the scientific research behind Giant Bio's recombinant collagen provides consumers with clear value references. The combination of scientific evidence, professional application, and innovative emotional engagement forms a strong bond between the brand and its users [9] - The practice of making advanced technology accessible not only translates into products but also ensures that consumers feel assured and confident in every usage scenario [9]

Core Viewpoint - CICC maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a 55% upside potential based on 25/23x P/E for 2026-2027 [1] Recent Events - On January 15, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2] - The approval of this product is expected to expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [2] Future Product Pipeline - The company has a rich pipeline for aesthetic medicine, with cross-linked neck wrinkle products receiving priority review status and cross-linked nasolabial fold products progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience expected to enhance future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kemei" collagen repair series and plans for brand upgrades and new product launches in 2026 [4] - In terms of marketing, the company has strengthened its collaboration with key influencers, such as launching a New Year gift box with Li Jiaqi, and plans to enhance its online influencer matrix and self-operated team while expanding offline coverage [4]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the new product, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product portfolio and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product mix, comprehensive channel network, and refined brand management [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Viewpoint - The company, Giant Bio (02367.HK), has received a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen and sodium hyaluronate composite solution, marking a significant advancement in its product offerings [1] Group 1: Product Approval - The product is the world's first recombinant collagen and sodium hyaluronate composite solution approved for improving cheek smoothness, indicating a pioneering position in the market [1] - The approval was achieved through a joint review of device and drug assessments, showcasing the company's robust regulatory compliance [1] Group 2: Market Expansion - The successful approval of this product expands the company's product matrix and highlights its ongoing technological research and industrialization capabilities [1] - The company aims to promote the product's market launch and distribution, leveraging a diverse product portfolio, comprehensive channel network, and refined brand management to meet consumer demands in various scenarios [1] - This development is expected to inject new growth momentum into the company's business in the skin rejuvenation sector, reinforcing its leading market position in health and beauty [1]

继重组I型α1亚型胶原蛋白冻干纤维之后，本产品的成功获批进一步拓展了本公司的产品矩阵，体现了 集团持续领先的技术研发和产业化实力，同时打开了更广阔的市场空间，为本公司在肌肤焕活领域的业 务发展注入新的增长动力。未来，本公司将稳步推进上述产品的上市推广与市场投放工作，通过多元的 产品组合、全面的渠道网络、精细的品牌运营，为更多场景下的消费者需求提供差异化的解决方案，不 断强化本公司在健康与美丽领域的领先市场地位。 本产品是全球首个用于改善面颊部平滑度的重组胶原蛋白和透明质酸钠复合溶液植入剂产品，通过器审 与药审联合审评正式获批。 智通财经APP讯，巨子生物(02367)发布公告，本公司全资子公司陕西巨子生物技术有限公司于今日收到 中国国家药品监督管理局颁发的关于重组I型α1亚型胶原蛋白及透明质酸钠复合溶液产品(本产品)的 《中华人民共和国医疗器械注册证》(注册证编号：国械注准20263130044)。本产品以重组胶原蛋白及 透明质酸钠为主要成分，用于真皮层的注射，以改善面颊部平滑度。 ...

Core Viewpoint - The company is optimistic about the recombinant collagen market, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry development [1] Group 1: Industry Insights - Recombinant collagen production occurs in controlled fermentation environments, mitigating risks associated with animal-derived collagen, such as viral transmission and allergic reactions [1] - The technology allows for precise production of recombinant collagen with specific amino acid sequences, enhancing targeted efficacy for various applications, including anti-wrinkle and tissue regeneration [1] - The fermentation process offers scalability and consistency, enabling low-cost, high-quality production, thus overcoming limitations faced by animal-derived collagen [1] Group 2: Company Performance - The company operates six brands centered around recombinant collagen, with key brands contributing over 95% of revenue; projected revenues for 2024 are 4.54 billion and 840 million for the two main brands, with compound annual growth rates of 73.4% and 11.8% respectively from 2021 to 2024 [2] - The company is facing short-term operational pressures due to market discussions surrounding the content and testing methods of recombinant collagen, impacting brand performance, particularly for its flagship product [2] - The company is shifting from reliance on a single product to a strategy of "multiple brands, multiple categories, and multiple channels" to address challenges [2] Group 3: Product Development and Market Strategy - Plans for 2026 include launching a medical device and five skincare lines, with marketing efforts focused on core products [3] - The company aims to enhance its brand presence through collaborations and expanding its retail footprint, including increasing coverage in approximately 150,000 pharmacies nationwide [3] - The medical aesthetics sector is identified as a strategic growth area, with plans to establish a dedicated division and expand into around 2,000 medical aesthetic institutions by 2026 [3] Group 4: Financial Projections - The company is rated "outperform" with a target price of 43.6 HKD, indicating a potential upside of 22.0%; revenue projections for 2025-2027 are 5.49 billion, 5.99 billion, and 6.69 billion respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [4] - Gross margins are projected to remain stable at around 80.5% to 79.2% from 2025 to 2027, while net profit margins are expected to decline slightly [4]

Investment Rating - The report initiates coverage with an OUTPERFORM rating for Giant Biogene, with a target price of HK$43.60, indicating a potential upside of 22.0% from the current price of HK$35.74 [1][2][7]. Core Insights - The report expresses a long-term positive outlook on the recombinant collagen sector, highlighting its advantages in safety, efficacy, and sustainability, which are seen as fundamental drivers for industry growth [4][34]. - Giant Biogene has established itself as a leader in the recombinant collagen market, with a strategic shift towards brand development in 2026 [9][30]. Financial Summary - Revenue projections for 2025, 2026, and 2027 are estimated at RMB 54.9 billion, RMB 59.9 billion, and RMB 66.9 billion, respectively, with expected growth rates of -0.9%, 9.1%, and 11.8% [7][32]. - Net profit forecasts for the same years are RMB 18.8 billion, RMB 20.0 billion, and RMB 22.1 billion, with growth rates of -9.0%, 6.6%, and 10.5% [7][32]. - The gross profit margin is expected to remain stable at approximately 80.5% in 2025, declining slightly to 79.2% by 2027 [7][32]. Brand and Product Strategy - Giant Biogene operates eight brands, with the core brands being Kefu Mei and Keli Jin, which contribute over 95% of the company's revenue [5][11][13]. - The company plans to launch a medical device and five skincare series in 2026, alongside a brand revamp for Keli Jin [6][30][31]. - The focus will be on expanding both online and offline channels, with plans to increase the number of physical stores and enhance partnerships with high-potential retailers [31][32]. Market Position and Challenges - The company faces short-term challenges due to discussions around the content and testing methods of recombinant collagen, which have impacted sales, particularly for the Kefu Mei brand [18][20][25]. - Despite these challenges, the company is adjusting its strategies, including enhancing online marketing and product offerings to stabilize and grow its market presence [25][29][30].